News headlines about CTI BioPharma (NASDAQ:CTIC) have trended somewhat positive on Thursday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. CTI BioPharma earned a news sentiment score of 0.07 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 47.1297345339546 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media stories that may have effected Accern’s scoring:
- Global End-Stage Renal Disease (ESRD) Drugs Market 2018 Dynamics – CTI BioPharma Corp, Merck & Co Inc … (thetricountypress.com)
- CTI BioPharma Corp. (CTIC) stock closes Friday with $4.90 (nasdaqfortune.com)
- Track P/E Before Buying A Stock – CTI BioPharma Corp. (NASDAQ:CTIC) (nasdaqjournal.com)
- Morning Miraculous Stocks: Precision Drilling Corporation (NYSE:PDS), CTI BioPharma Corp. (NASDAQ:CTIC … (journalfinance.net)
- Stocks Views And Recommendations: Palatin Technologies, Inc. (NYSE:PTN), CTI BioPharma Corp. (NASDAQ:CTIC … (journalfinance.net)
CTI BioPharma opened at $4.79 on Thursday, Marketbeat Ratings reports. CTI BioPharma has a 1-year low of $2.45 and a 1-year high of $4.99. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.30 and a current ratio of 5.32. The firm has a market capitalization of $277.13 million, a P/E ratio of -3.86 and a beta of 0.14.
CTI BioPharma (NASDAQ:CTIC) last issued its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.02. The company had revenue of $10.48 million for the quarter, compared to analyst estimates of $10.30 million. CTI BioPharma had a negative net margin of 71.30% and a negative return on equity of 63.27%. analysts forecast that CTI BioPharma will post -0.95 earnings per share for the current fiscal year.
A number of brokerages have recently issued reports on CTIC. ValuEngine upgraded shares of CTI BioPharma from a “strong sell” rating to a “sell” rating in a research report on Tuesday, May 8th. Zacks Investment Research upgraded shares of CTI BioPharma from a “sell” rating to a “hold” rating in a research report on Wednesday, April 25th. Needham & Company LLC began coverage on shares of CTI BioPharma in a research report on Monday, March 26th. They issued a “buy” rating and a $10.00 price objective on the stock. Cann reiterated a “buy” rating and issued a $5.00 price objective on shares of CTI BioPharma in a research report on Wednesday, March 7th. Finally, JMP Securities began coverage on shares of CTI BioPharma in a research report on Wednesday, March 7th. They issued an “outperform” rating and a $8.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $6.42.
CTI BioPharma Company Profile
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.